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variable is per capita pharmaceutical and other medical non-
durable expenditures. Explanatory variables investigated include
per capita GDP (Gross Domestic Product), % of elderly popu-
lation (65+ years), % of population with higher education
(college+), school expectancy, calorie intake per capita per day,
alcohol consumption in liters per capita (age 15+), % of expen-
ditures on pharmaceuticals and other medical non-durables
ﬁnanced by the public sector, number of practicing physicians,
% of population with public health care coverage, number of
doctor consultations per capita and % urbanized. All monetary
values were converted into US dollars based on GDP purchasing
power parity. A log-linear (constant elasticity) regression model
was used. RESULTS: The ﬁnal model included 6 explanatory
variables with an adjusted R2 = 0.744. The White test was used
to correct heteroskedasticity. The natural log of GDP per capita
(b = 0.455, p = 0.003), percent of elderly population (b = 0.039,
p = 0.01), number of doctor consultations (b = 0.028, p = 0.008),
and calories intake (b = 0.0003, p = 0.002) had positive, statis-
tically signiﬁcant effects on pharmaceutical expenditures at á 
< 0.01. Percent of population with higher education (b = 0.012,
p = 0.22) and public ﬁnancing (b = -0.001, p = 0.43) were not
signiﬁcant. Alcohol consumption (another indicator of lifestyle
behaviors); number of physicians and public health care cover-
age (indicators of relative size of the health care system); urban-
ization (indicator of development); and school expectancy
(another indicator of educational development) did not con-
tribute to the model. CONCLUSIONS: OECD countries with
more wealth, more elderly people, more doctor consultations,
and more calorie intake tend to spend more on pharmaceuticals
and other medical non-durables. Size of the health care system
and ﬁnancing methods do not explain differences in pharma-
ceutical expenditures.
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OBJECTIVES: All approved pharmaceutical products in Korea
are available for reimbursement except some products on the
negative list. The aim of this study is to examine how many prod-
ucts are actually prescribed by doctors and to compare the 
prescribing patterns in inpatient and outpatient settings.
METHODS: Prescription data were obtained from the Korean
National Health Insurance claims database of April 2004 for all
the hospitals and clinics in Korea. The numbers of prescribed
products and ingredients were calculated along with the drug
expenditure incurred. RESULTS: In April 2004, 19,452 phar-
maceutical products (5120 ingredients) were on the list of reim-
bursable drug formulary. Among them 9423 products (3208
ingredients), 48.2% of the reimbursable products, were actually
prescribed for inpatients. For outpatients, 11,823 products
(3731 ingredients), 60.8% of reimbursable products, were pre-
scribed. Although more than 9000 pharmaceutical products
were prescribed by doctors, top quintile high-expenditure drugs
of 1885 took up 94% of total drug expenditure for inpatients,
whereas top quintile 2365 products did 91.5% for outpatients.
Also, top quintile high-expenditure ingredients of 632 accounted
for 93% of total drug expenditure for inpatients, whereas those
of 746 ingredients did 92% for outpatients. CONCLUSIONS:
Unlike in western societies, more products and ingredients were
prescribed for outpatients than for inpatients in Korea. This
study also showed that although various pharmaceutical prod-
ucts were prescribed, the top 20% (high-expenditure drugs) of
all products and ingredients took up the lion’s share of total drug
expenditure. It suggests that there is a need of introduction 
of positive list formulary system for the efﬁcient drug beneﬁt
management.
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OBJECTIVES: In Ukraine the government authorizes the State
program of maintenance of the population by medical products
for 2004–2010, which provides use of pharmacoeconomic analy-
sis methods. The State Formulary for pharmaceutical provision
are formed. METHODS: We have analyzed all available phar-
macoeconomic studies published in Ukraine for 1998–2004 to
assess methodological problems and potential for future use of
pharmacoeconomics in drug policy. RESULTS: We have estab-
lished, that the quantity of published pharmacoeconomic
researches has increased in 7.3 times. Methodological quality is
generally insufﬁcient. Cost-minimization is the preferred tech-
nique although differences in effectiveness are not properly
assessed. Few studies desribe costing and cost-effectiveness
methodologies. Modeling studies are weak due absence of epi-
demiological and economical database. Societal perspective is
rarely used—the health care perspective prevails. Little study
exist in Qol measurement and cost-utility techniques. Industry
use of pharmacoeconomics is mainly for supporting marketing
and sales. Physicians are increasingly receptive of pharmaco-
economic analysis, but little value on modeling approaches. We
develop methodical recommendations on use of pharmaco-
economic analysis methods in Ukraine, authorized by Ministry
of Health. We have conducted the analysis of consumption of
antidiabetic agents in the deﬁned daily doses. We published 
the circular “A Technique of pharmacoeconomical analysis 
‘cost-effectiveness’ for deﬁnition of need in medicinal tools in
Ukraine”. CONCLUSION: Pharmacoeconomics must improve
methodological standarts in Ukraine. This is a task for both 
government and industry with the purpose of creation of State
Formulary.
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OBJECTIVES: To investigate the quality and completeness of
economic models submitted by pharmaceutical manufacturers to
health plans under the Academy of Managed Care Pharmacy
(AMCP) Format for formulary submissions, and to compare eco-
nomic models of “me-too” versus drugs judged to have signiﬁ-
cant competitive edge. METHODS: We analyzed economic
models included in AMCP-Format dossiers submitted by phar-
maceutical companies to the pharmacy services staff of Premera
Blue Cross (Mountlake Terrace, WA, enrollment 1.5 million) in
2003. “Economic models” were deﬁned as mathematical simu-
lations that combined clinical and cost data to estimate the eco-
nomic value of a drug. We assessed models’ compliance with
criteria recommended by the Panel on Cost-Effectiveness in
Health and Medicine, including: justiﬁcation of model type;
statement of time horizon and discount rate; discussion and
reporting of productivity changes; separate reporting of resource
quantities from prices; comparison against relevant alternatives;
